Cenerimod not checked
Viatris Innovation GmbH · ACT-334441
FollowEvery change as it happens, and a Monday email
Trials
5 active
14 in total · 5 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Cenerimod will be supplied as film-coated tablets at the dose of 4 mg.”In the company’s words, NCT05672576 on ClinicalTrials.gov
- Tested for
- Lupus Erythematosus, Systemic (4 trials), Nephritis, Lupus, SLE - Systemic Lupus Erythematosus
- Main trialPhase 3
- “The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to severe symptoms. The main questions it aims to answer are: * How well cenerimod works on top of the treatment already being administered. * How safe cenerimod is for adult patients with Systemic Lupus Erythematosus. Researchers will compare one dose of cenerimod and a placebo to see how well cenerimod works when it is added to the treatment already being administered. In this research study approximately 210 participants will receive cenerimod and…”In the company’s words, NCT05672576 on ClinicalTrials.gov
- Other names
- ACT-334441
Other drugs for Lupus Erythematosus, Systemic
- IanalumabNovartis Pharmaceuticals · Phase 3
- UpadacitinibAbbVie · Phase 3
- QL1074Qilu Pharmaceutical · Phase 3
- Dapirolizumab pegolUCB Biopharma SRL · Phase 3
- Mycophenolate MofetilRoche · Phase 3
- ObinutuzumabRoche · Phase 3
Coming up5
- 31 DecPhase 3 trial completes · ClinicalTrials.gov
- 31 Mar 2027Phase 3 trial completes · ClinicalTrials.gov
- 8 Oct 2027Phase 2 trial completes · ClinicalTrials.gov
- Aug 2029Phase 3 trial completes · ClinicalTrials.gov
- Sep 2032Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials14
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 Dec 2026 | A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | |
| Phase 3Active, not recruiting | 31 Mar 2027 | A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | |
| Phase 3Recruiting | Aug 2029 | A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment | |
| Phase 3Enrolling by invitation | Sep 2032 | Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus | |
| Phase 2Active, not recruiting | 8 Oct 2027 | A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE) | |
| Phase 2Completed | 31 Aug 2021 | Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus | |
| Phase 1/2Completed | 23 Jan 2017 | Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus | |
| Phase 1Terminated | 1 May 2016 | Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441 | |
| Phase 1Completed | 1 Dec 2016 | A Study to Evaluate Cenerimod in Healthy Male Subjects | |
| Phase 1Completed | 29 Oct 2019 | Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects | |
| Phase 1Completed | 14 Sep 2021 | To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men. | |
| Phase 1Completed | 27 Jul 2023 | The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics | |
| Phase 1Completed | 18 Aug 2024 | A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod | |
| Phase 1Completed | 18 Mar 2026 | A Trial to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026